Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
178 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ischemia Reperfusion Injury - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Ischemia Reperfusion Injury - Pipeline Review, H2 2015', provides an overview of the Ischemia Reperfusion Injury's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ischemia Reperfusion Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ischemia Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ischemia Reperfusion Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Ischemia Reperfusion Injury Overview 8 Therapeutics Development 9 Pipeline Products for Ischemia Reperfusion Injury - Overview 9 Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis 10 Ischemia Reperfusion Injury - Therapeutics under Development by Companies 11 Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes 14 Ischemia Reperfusion Injury - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Ischemia Reperfusion Injury - Products under Development by Companies 19 Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes 21 Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 23 Alligator Bioscience AB 23 Angion Biomedica Corp. 24 Antipodean Pharmaceuticals, Inc. 25 Biomedica Management Corporation 26 Bolder Biotechnology, Inc. 27 Curatis Pharma GmbH 28 Enteris BioPharma, Inc. 29 Erimos Pharmaceuticals, LLC (Inactive) 30 Gilead Sciences, Inc. 31 Ischemix 32 Kowa Company, Ltd. 33 LG Life Science LTD. 34 Omeros Corporation 35 Opsona Therapeutics Limited 36 Peptinnovate Limited 37 Pharming Group N.V. 38 PledPharma AB 39 Prolong Pharmaceuticals 40 Proteo, Inc. (Inactive) 41 Prothix BV 42 Trophos SA 43 Zealand Pharma A/S 44 Ischemia Reperfusion Injury - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Target 46 Assessment by Mechanism of Action 49 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 ADC-1004 - Drug Profile 56 AM/AMBP-1 - Drug Profile 57 Annexin A-1 - Drug Profile 60 ANV-6L15 - Drug Profile 61 APP-103 - Drug Profile 62 BB-3 - Drug Profile 63 BBT-059 - Drug Profile 66 C1 esterase inhibitor (human) - Drug Profile 67 CMX-2043 - Drug Profile 72 CRX-526 - Drug Profile 74 Curaglutide - Drug Profile 75 danegaptide - Drug Profile 76 Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile 78 EP-80317 - Drug Profile 79 GS-459679 - Drug Profile 80 KN-93 - Drug Profile 81 mangafodipir trisodium - Drug Profile 83 MG-53 - Drug Profile 84 mirococept - Drug Profile 86 MitoQ - Drug Profile 88 Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile 90 Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - Drug Profile 91 Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile 93 MTP-131 - Drug Profile 94 NBD Peptide - Drug Profile 96 NecX - Drug Profile 98 Neutrolide - Drug Profile 99 NP-202 - Drug Profile 101 Oligonucleotide for Oncology and Cardiovascular - Drug Profile 103 OMS-721 - Drug Profile 104 OPN-305 - Drug Profile 106 PAC-G31P - Drug Profile 108 PIN-201601 - Drug Profile 110 pitavastatin NP - Drug Profile 111 PRO-02 - Drug Profile 112 R-190 - Drug Profile 113 Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile 115 Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury - Drug Profile 116 Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile 117 Recombinant Proteins for Ischemia Reperfusion Injury - Drug Profile 118 Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 119 Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 120 Sanguinate - Drug Profile 121 Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 123 Small Molecules for Ischemia Reperfusion Injury - Drug Profile 124 Small Molecules for Ischemia Reperfusion Injury - Drug Profile 125 Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 126 Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 127 Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 128 SMTP-7 - Drug Profile 129 Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 130 Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 131 terameprocol - Drug Profile 132 tiprelestat - Drug Profile 134 TRO-40303 - Drug Profile 137 UCF-101 - Drug Profile 139 UWA-TAT - Drug Profile 140 Ischemia Reperfusion Injury - Recent Pipeline Updates 141 Ischemia Reperfusion Injury - Dormant Projects 160 Ischemia Reperfusion Injury - Discontinued Products 164 Ischemia Reperfusion Injury - Product Development Milestones 165 Featured News & Press Releases 165 Appendix 173 Methodology 173 Coverage 173 Secondary Research 173 Primary Research 173 Expert Panel Validation 173 Contact Us 173 Disclaimer 174
List of Tables
Number of Products under Development for Ischemia Reperfusion Injury, H2 2015 13 Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H2 2015 14 Number of Products under Development by Companies, H2 2015 16 Number of Products under Development by Companies, H2 2015 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2015 18 Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 19 Comparative Analysis by Late Stage Development, H2 2015 20 Comparative Analysis by Clinical Stage Development, H2 2015 21 Comparative Analysis by Early Stage Development, H2 2015 22 Products under Development by Companies, H2 2015 23 Products under Development by Companies, H2 2015 (Contd..1) 24 Products under Investigation by Universities/Institutes, H2 2015 25 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 26 Ischemia Reperfusion Injury - Pipeline by Alligator Bioscience AB, H2 2015 27 Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp., H2 2015 28 Ischemia Reperfusion Injury - Pipeline by Antipodean Pharmaceuticals, Inc., H2 2015 29 Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corporation, H2 2015 30 Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology, Inc., H2 2015 31 Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H2 2015 32 Ischemia Reperfusion Injury - Pipeline by Enteris BioPharma, Inc., H2 2015 33 Ischemia Reperfusion Injury - Pipeline by Erimos Pharmaceuticals, LLC (Inactive), H2 2015 34 Ischemia Reperfusion Injury - Pipeline by Gilead Sciences, Inc., H2 2015 35 Ischemia Reperfusion Injury - Pipeline by Ischemix, H2 2015 36 Ischemia Reperfusion Injury - Pipeline by Kowa Company, Ltd., H2 2015 37 Ischemia Reperfusion Injury - Pipeline by LG Life Science LTD., H2 2015 38 Ischemia Reperfusion Injury - Pipeline by Omeros Corporation, H2 2015 39 Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Limited, H2 2015 40 Ischemia Reperfusion Injury - Pipeline by Peptinnovate Limited, H2 2015 41 Ischemia Reperfusion Injury - Pipeline by Pharming Group N.V., H2 2015 42 Ischemia Reperfusion Injury - Pipeline by PledPharma AB, H2 2015 43 Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals, H2 2015 44 Ischemia Reperfusion Injury - Pipeline by Proteo, Inc. (Inactive), H2 2015 45 Ischemia Reperfusion Injury - Pipeline by Prothix BV, H2 2015 46 Ischemia Reperfusion Injury - Pipeline by Trophos SA, H2 2015 47 Ischemia Reperfusion Injury - Pipeline by Zealand Pharma A/S, H2 2015 48 Assessment by Monotherapy Products, H2 2015 49 Number of Products by Stage and Target, H2 2015 51 Number of Products by Stage and Mechanism of Action, H2 2015 54 Number of Products by Stage and Route of Administration, H2 2015 57 Number of Products by Stage and Molecule Type, H2 2015 59 Ischemia Reperfusion Injury Therapeutics - Recent Pipeline Updates, H2 2015 145 Ischemia Reperfusion Injury - Dormant Projects, H2 2015 164 Ischemia Reperfusion Injury - Dormant Projects (Contd..1), H2 2015 165 Ischemia Reperfusion Injury - Dormant Projects (Contd..2), H2 2015 166 Ischemia Reperfusion Injury - Dormant Projects (Contd..3), H2 2015 167 Ischemia Reperfusion Injury - Discontinued Products, H2 2015 168
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
